Radium-223 Dichloride Long-term Follow-up Program
Public ClinicalTrials.gov record NCT02312960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
Study identification
- NCT ID
- NCT02312960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 255 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2014
- Primary completion
- Jan 30, 2024
- Completion
- Jan 30, 2024
- Last update posted
- Mar 24, 2025
2014 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anchorage | Alaska | 99503 | — |
| Not listed | Tucson | Arizona | 85704 | — |
| Not listed | Plantation | Florida | 33324 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Ashland | Kentucky | 41101 | — |
| Not listed | New Orleans | Louisiana | 70112 | — |
| Not listed | Shreveport | Louisiana | 71103 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Omaha | Nebraska | 68130 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Not listed | Pittsburgh | Pennsylvania | 15215 | — |
| Not listed | Watertown | South Dakota | 57201 | — |
| Not listed | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02312960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02312960 live on ClinicalTrials.gov.